Literature DB >> 26260795

Critical Role of the Neonatal Fc Receptor (FcRn) in the Pathogenic Action of Antimitochondrial Autoantibodies Synergizing with Anti-desmoglein Autoantibodies in Pemphigus Vulgaris.

Yumay Chen1, Alex Chernyavsky2, Robert J Webber3, Sergei A Grando4, Ping H Wang5.   

Abstract

Pemphigus vulgaris (PV) is a life-long, potentially fatal IgG autoantibody-mediated blistering disease targeting mucocutaneous keratinocytes (KCs). PV patients develop pathogenic anti-desmoglein (Dsg) 3 ± 1 and antimitochondrial antibodies (AMA), but it remained unknown whether and how AMA enter KCs and why other cell types are not affected in PV. Therefore, we sought to elucidate mechanisms of cell entry, trafficking, and pathogenic action of AMA in PV. We found that PVIgGs associated with neonatal Fc receptor (FcRn) on the cell membrane, and the PVIgG-FcRn complexes entered KCs and reached mitochondria where they dissociated. The liberated AMA altered mitochondrial membrane potential, respiration, and ATP production and induced cytochrome c release, although the lack or inactivation of FcRn abolished the ability of PVIgG to reach and damage mitochondria and to cause detachment of KCs. The assays of mitochondrial functions and keratinocyte adhesion demonstrated that although the pathobiological effects of AMA on KCs are reversible, they become irreversible, leading to epidermal blistering (acantholysis), when AMA synergize with anti-Dsg antibodies. Thus, it appears that AMA enter a keratinocyte in a complex with FcRn, become liberated from the endosome in the cytosol, and are trafficked to the mitochondria, wherein they trigger pro-apoptotic events leading to shrinkage of basal KCs uniquely expressing FcRn in epidermis. During recovery, KCs extend their cytoplasmic aprons toward neighboring cells, but anti-Dsg antibodies prevent assembly of nascent desmosomes due to steric hindrance, thus rendering acantholysis irreversible. In conclusion, FcRn is a common acceptor protein for internalization of AMA and, perhaps, for PV autoantibodies to other intracellular antigens, and PV is a novel disease paradigm for investigating and elucidating the role of FcRn in this autoimmune disease and possibly other autoimmune diseases.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  antibody; antigen; autoimmunity; keratinocyte; mitochondria; mitochondrial apoptosis; pemphigus; skin

Mesh:

Substances:

Year:  2015        PMID: 26260795      PMCID: PMC4583029          DOI: 10.1074/jbc.M115.668061

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Novel markers of squamous differentiation in the urinary bladder.

Authors:  Wenbin Huang; Sean R Williamson; Qiu Rao; Antonio Lopez-Beltran; Rodolfo Montironi; John N Eble; David J Grignon; Muhammad T Idrees; Robert E Emerson; Xiao-Jun Zhou; Shaobo Zhang; Lee Ann Baldridge; Noah M Hahn; Mingsheng Wang; Michael O Koch; Liang Cheng
Journal:  Hum Pathol       Date:  2013-06-24       Impact factor: 3.466

2.  Pemphigus vulgaris antibodies target the mitochondrial nicotinic acetylcholine receptors that protect keratinocytes from apoptolysis.

Authors:  Alex Chernyavsky; Yumay Chen; Ping H Wang; Sergei A Grando
Journal:  Int Immunopharmacol       Date:  2015-05-18       Impact factor: 4.932

3.  Mitochondria express several nicotinic acetylcholine receptor subtypes to control various pathways of apoptosis induction.

Authors:  Olena Lykhmus; Galyna Gergalova; Lyudmyla Koval; Maxim Zhmak; Sergiy Komisarenko; Maryna Skok
Journal:  Int J Biochem Cell Biol       Date:  2014-05-29       Impact factor: 5.085

4.  α7 nicotinic acetylcholine receptors control cytochrome c release from isolated mitochondria through kinase-mediated pathways.

Authors:  Galyna Gergalova; Olena Lykhmus; Sergiy Komisarenko; Maryna Skok
Journal:  Int J Biochem Cell Biol       Date:  2014-01-09       Impact factor: 5.085

5.  Divergent outcomes following transcytosis of IgG targeting intracellular and extracellular chlamydial antigens.

Authors:  Charles W Armitage; Connor P O'Meara; Marina C G Harvie; Peter Timms; Richard S Blumberg; Kenneth W Beagley
Journal:  Immunol Cell Biol       Date:  2014-01-21       Impact factor: 5.126

Review 6.  Autoimmunity to keratinocyte acetylcholine receptors in pemphigus.

Authors:  S A Grando
Journal:  Dermatology       Date:  2000       Impact factor: 5.366

7.  Low pathogenicity of anti-desmoglein 3 immunoglobulin G autoantibodies contributes to the atypical clinical phenotypes in pemphigus.

Authors:  Marwah A Saleh; Rena Hashimoto; Yuko Kase; Masayuki Amagai; Jun Yamagami
Journal:  J Dermatol       Date:  2015-04-24       Impact factor: 4.005

Review 8.  Targeting FcRn for therapy: from live cell imaging to in vivo studies in mice.

Authors:  E Sally Ward; Ramraj Velmurugan; Raimund J Ober
Journal:  Immunol Lett       Date:  2014-02-23       Impact factor: 3.685

9.  Mechanisms of mitochondrial damage in keratinocytes by pemphigus vulgaris antibodies.

Authors:  Mina Kalantari-Dehaghi; Yumay Chen; Wu Deng; Alex Chernyavsky; Steve Marchenko; Ping H Wang; Sergei A Grando
Journal:  J Biol Chem       Date:  2013-04-18       Impact factor: 5.157

10.  Nanorobotic investigation identifies novel visual, structural and functional correlates of autoimmune pathology in a blistering skin disease model.

Authors:  Kristina Seiffert-Sinha; Ruiguo Yang; Carmen K Fung; King W Lai; Kevin C Patterson; Aimee S Payne; Ning Xi; Animesh A Sinha
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

View more
  25 in total

Review 1.  Pemphigus.

Authors:  Michael Kasperkiewicz; Christoph T Ellebrecht; Hayato Takahashi; Jun Yamagami; Detlef Zillikens; Aimee S Payne; Masayuki Amagai
Journal:  Nat Rev Dis Primers       Date:  2017-05-11       Impact factor: 52.329

Review 2.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 3.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

Review 4.  Setting the target for pemphigus vulgaris therapy.

Authors:  Christoph T Ellebrecht; Aimee S Payne
Journal:  JCI Insight       Date:  2017-03-09

5.  Synergy among non-desmoglein antibodies contributes to the immunopathology of desmoglein antibody-negative pemphigus vulgaris.

Authors:  Alex Chernyavsky; Kyle T Amber; Arianna F Agnoletti; Candice Wang; Sergei A Grando
Journal:  J Biol Chem       Date:  2019-01-28       Impact factor: 5.157

Review 6.  Apoptolysis: a less understood concept in the pathogenesis of Pemphigus Vulgaris.

Authors:  Pratibha Ramani; Renu Ravikumar; Deepak Pandiar; K Monica; Reshma Poothakulath Krishnan; Abilasha Ramasubramanian; Gheena Sukumaran
Journal:  Apoptosis       Date:  2022-04-20       Impact factor: 4.677

Review 7.  Rituximab therapy in pemphigus and other autoantibody-mediated diseases.

Authors:  Nina A Ran; Aimee S Payne
Journal:  F1000Res       Date:  2017-01-27

Review 8.  Non-Desmoglein Antibodies in Patients With Pemphigus Vulgaris.

Authors:  Kyle T Amber; Manuel Valdebran; Sergei A Grando
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

Review 9.  Autoantibody Signaling in Pemphigus Vulgaris: Development of an Integrated Model.

Authors:  Thomas Sajda; Animesh A Sinha
Journal:  Front Immunol       Date:  2018-04-19       Impact factor: 7.561

10.  Keratinocyte Binding Assay Identifies Anti-Desmosomal Pemphigus Antibodies Where Other Tests Are Negative.

Authors:  Federica Giurdanella; Albertine M Nijenhuis; Gilles F H Diercks; Marcel F Jonkman; Hendri H Pas
Journal:  Front Immunol       Date:  2018-04-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.